Tag T-Cell Lymphoma

Wen-Hsuan Wendy Lin, MD, PhD

Researcher Spotlight: Wen-Hsuan Wendy Lin, MD, PhD COLUMBIA UNIVERSITY Peripheral T-cell lymphomas (PTCL) represent a group of aggressive blood cancers with poor outcomes. A common phenomenon in PTCL is the development of a proinflammatory microenvironment, in which lymphoma cells recruit…

Christopher Sauter, MD

Researcher Spotlight: Christopher Sauter, MD Perelman School of Medicine, University of Pennsylvania Chimeric antigen receptor (CAR) T-cell therapies work by harnessing the power of T cells to kill lymphoma cells through a variety of cytotoxic mechanisms that are coordinated simultaneously.…

Anouchka Laurent, PhD

Researcher Spotlight: Anouchka Laurent, PhD Columbia University in the City of New York Understanding the mechanisms and molecules involved in the formation of T-cell lymphomas (TCL) can illuminate new potential targets for drug development. Dr. Laurent’s research is focused on…

Tayla Heavican-Foral, PhD

Researcher Spotlight: Tayla Heavican-Foral, PhD DANA-FARBER CANCER INSTITUTE DR. OLIVER PRESS MEMORIAL FELLOW HEALTH EQUITY INITIATIVE Despite treatment advances in the lymphoma space, many patients with T-cell lymphomas (TCL) still experience limited response rates, often lasting for short durations, with…

Tayla Foral, PhD

Researcher Spotlight: Tayla Foral, PhD DANA-FARBER CANCER INSTITUTE Mature T-cell lymphomas (TCL) are a highlyheterogeneous group of diseases with poor treatment options. Currently, many patients with TCL experience relapsed or refractory disease, and outcomes are generally poor. Dr. Foral’s LRF…

Paola Ghione, MD

Researcher Spotlight: Paola Ghione, MD MEMORIAL SLOAN KETTERING CANCER CENTER Lymphomas are a highly heterogeneous set of diseases, and while many people will do well with treatment, there are subsets of patients whose cancer does not respond or relapses quickly…

Edmond Feris, PhD

Researcher Spotlight: Edmond Feris, PhD  Dartmouth-Hitchcock Norris Cotton Cancer Center Some of the most critical oncogenes responsible fortumor formation in humans are transcription factors. Dr.Feris’ LRF research project focuses on the study of howtranscriptional dysregulation can lead to carcinogenesis(the process…

Marco Ruella, MD

Researcher Spotlight: Marco Ruella, MD Perelman School of Medicine, University of Pennsylvania Chimeric antigen receptor (CAR) T cell therapy has been very successful in certain cancers, such as B-cell leukemia and lymphoma. However, the needle has not moved for most…

Owen A. O’Connor, MD, PhD

Researcher Spotlight: Owen A. O’Connor, MD, PhD Columbia University Medical Center A long-time member of the Lymphoma Research Foundation’s Scientific Advisory Board , and a founding Executive Committee member of LRF’s Mantle Cell Lymphoma Consortium, Dr. Owen O’Connor has been…